pharmaphorum56s
New UK biotech Swarm lands with T-cell therapy mission
Swarm was formed in 2022 and has now emerged with Martin Olin – previously chief executive of BerGenBio and Symphogen – at ...
Quince Therapeutics Announces Frontiers in Neurology Publication of Long-Term Safety of EryDex in Pediatric Patients with Ataxia-Telangiectasia
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s ...
BIA report: UK biotech investment surged to £3.5bn in 2024
The UK biotech sector raised £3.5bn in 2024, marking a 94% increase from the previous year, according to the BioIndustry ...
Maze Therapeutics targets up to $728 million valuation in US IPO
(Reuters) -Drug developer Maze Therapeutics said on Monday it was targeting a valuation of as much as $728.1 million in its initial public offering in the United States. The South San Francisco, ...